- TV Footage
- Integrated Annual Reports
- Quarterly Statements
- Sustainability Report
- Newsletter Overview
- Social Media
- Media Contact
About Bayer in Hemophilia
Bayer is driven by helping people with hemophilia thrive. We have a deep understanding of the evolving needs and aspirations of people with hemophilia, established around 30 years of partnering with the hemophilia community. FVIII replacement treatments, the standard of care to stop or prevent bleeding, could offer people with hemophilia A across all stages of life a treatment to suit their individual needs and lifestyles. Bayer’s FVIII treatments include Kogenate FS® (Kogenate BAYER®), Kovaltry® and candidate BAY94-9027, which has been submitted in the US, EU and Japan for marketing authorization approval. We work together with researchers, healthcare professionals and patient groups to build a strong community and help people with hemophilia live fulfilling lives. Bayer is passionate about spearheading research and investing in developing the next-generation of therapies and solutions to help people with hemophilia thrive both now and in the future.
About Hemophilia A
Hemophilia affects approximately 400,000 people around the world and is a largely inherited disorder where one of the proteins needed to form blood clots is missing or reduced. Hemophilia A, the most common type of hemophilia, in which blood clotting is impaired because there is a lack or defect of coagulation FVIII. Therefore patients without sufficient therapy repeatedly experience bleeds in muscles, joints or other tissues, which can result in chronic joint damage over time. External injuries can have severe consequences if not treated appropriately, as the blood clots more slowly in these patients than in healthy individuals. Hemophilia A has an estimated frequency of 1 in 5,000 male live births, affecting approximately 12,500 patients in China today.
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2017, the Group employed around 99,800 people and had sales of EUR 35.0 billion. Capital expenditures amounted to EUR 2.4 billion, R&D expenses to EUR 4.5 billion. For more information, go to www.bayer.com.
Find more information at www.pharma.bayer.com.
Follow us on Facebook: http://www.facebook.com/pharma.bayer
Follow us on Twitter: @BayerPharma
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
View Download Center